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OPENPost-discharge kidney function is associated with
among survivors of acute kidney injury
Simon Sawhney1,2, Angharad Marks1,2, Nick Fluck2, Adeera Levin3, David McLernon1, Gordon Prescott1
and Corri Black1,2
1University of Aberdeen, Aberdeen, UK; 2NHS Grampian, Aberdeen, UK; and 3University of British Columbia,
British Columbia, CanadaThe extent to which renal progression after acute kidney
injury (AKI) arises from an initial step drop in kidney
function (incomplete recovery), or from a long-term
trajectory of subsequent decline, is unclear. This makes it
challenging to plan or time post-discharge follow-up. This
study of 14651 hospital survivors in 2003 (1966 with AKI,
12685 no AKI) separates incomplete recovery from
subsequent renal decline by using the post-discharge
estimated glomerular ﬁltration rate (eGFR) rather than the
pre-admission as a new reference point for determining
subsequent renal outcomes. Outcomes were sustained 30%
renal decline and de novo CKD stage 4, followed from
2003-2013. Death was a competing risk. Overall, death was
more common than subsequent renal decline (37.5% vs
11.3%) and CKD stage 4 (4.5%). Overall, 25.7% of AKI
patients had non-recovery. Subsequent renal decline was
greater after AKI (vs no AKI) (14.8% vs 10.8%). Renal decline
after AKI (vs no AKI) was greatest among those with higher
post-discharge eGFRs with multivariable hazard ratios of
2.29 (1.88-2.78); 1.50 (1.13-2.00); 0.94 (0.68-1.32) and 0.95
(0.64-1.41) at eGFRs of 60 or more; 45-59; 30-44 and under
30, respectively. The excess risk after AKI persisted over ten
years of study, irrespective of AKI severity, or post-episode
proteinuria. Thus, even if post-discharge kidney function
returns to normal, hospital admission with AKI is associated
with increased renal progression that persists for up to ten
years. Follow-up plans should avoid false reassurance when
eGFR after AKI returns to normal.
Kidney International (2017) 92, 440–452; http://dx.doi.org/10.1016/
j.kint.2017.02.019
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440A cute kidney injury (AKI) is common and associatedwith poor renal outcomes,1 but the clinical course isnot well understood.2–4 One reason for the increase in
advanced chronic kidney disease (CKD) after AKI (vs. no
AKI) is “nonrecovery,” that is, the occurrence of a step drop in
estimated glomerular ﬁltration rate (eGFR) during the AKI
episode, which does not return to baseline once the episode
has ended (Figure 1, pink dashed line). However, another
path to advanced CKD after AKI may be a trajectory of
subsequent renal decline after the episode has ended (Figure 1,
red solid line). This distinction between subsequent pro-
gression and nonrecovery is crucial in clinical practice. At the
time of a post-discharge clinical review, future subsequent
renal decline is uncertain, whereas the extent of nonrecovery
can already be observed. Moreover, because the trajectory of
renal decline can vary from a gradual to a catastrophic loss of
function,5 both hard outcomes (e.g., de novo long-term renal
replacement therapy [RRT] or CKD stage 4) and intermediate
outcomes (e.g., a 30% drop in kidney function)6 are impor-
tant for clinicians and their patients to understand when
planning care.
The Kidney Disease: Improving Global Outcomes AKI
guidelines provide advice for post-AKI management based on
expert opinion but without graded evidence.7 They state that
people with AKI should be re-evaluated for resolution of kidney
function and receive care based on CKD guidelines if they have
developed CKD. However, this guidance does not apply to those
who have had an episode of AKI and recovered to normal levels
of kidney function after the episode. The relevance of post-
episode recovery to baseline as a stratifying risk factor for AKI
outcomes has been previously recognized in some studies but
not in others.8 This is because previous studies have dichoto-
mized recovery as being present or absent, with each using
different cutoff values, but in reality, a spectrumof renal recovery
exists.9,10Moreover, even if patients could be adequately grouped
by recovery status, the use of a pre-episode baseline for deter-
mining outcomes would not separate the initial progression
caused by incomplete recovery (however slight) from the sub-
sequent progression caused by ongoing decline. The solution in
clinical practice is that a clinician will wait to see where a post-
episode eGFR ﬁnally settles (which becomes the “new base-
line”) before evaluating risk and planning care from that point
on. Therefore this is the approach we adopted in our analysis.Kidney International (2017) 92, 440–452
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Figure 1 | Renal progression after acute kidney injury (AKI) caused by renal decline (red solid line) or nonrecovery (pink dashed line). A
patient with AKI who has incomplete post-episode recovery has a high risk of developing advanced chronic kidney disease (CKD) even if
subsequent renal decline is slow (pink dashed line). However, the risk of advanced CKD in a patient with AKI who has near-complete recovery
depends on whether he or she experiences subsequent decline at a rapid trajectory (red solid line). In both cases at a post-AKI reassessment
review (time d), renal recovery and post-episode kidney function are already observable, but the risk of subsequent decline is uncertain. The
vertical black dashed line at time d represents the start of follow-up in this study. eGFR, estimated glomerular ﬁltration rate.
S Sawhney et al.: Renal progression in AKI survivors c l i n i ca l i nves t iga t ionIn this large population study, we evaluated whether a
completed AKI episode was still associated with subsequent
renal decline, after allowing for a variable extent of initial
renal recovery to baseline once the episode has ended. We
isolated subsequent renal decline by using post-episode eGFR
as the reference for subsequent renal outcomes. We hypoth-
esized that more patients with AKI (vs. no AKI) would
experience ongoing renal decline (a 30% eGFR drop),
resulting in more patients with AKI having CKD stage 4.
RESULTS
Population
Of 17,630 patients with an index hospital admission in 2003,
14,651 patients were alive and not receiving long-term RRT 1
year after index hospital admission (Figure 2). This included
1966 with AKI and 12,685 without AKI. For the study of de
novo CKD stage 4, an additional 545 patients who already had
eGFR < 30 ml/min per 1.73 m2 at study entry were excluded.
Thus 14,651 patients were available for the study of renal
decline and 14,106 for the study of de novo CKD stage 4. The
follow-up period of the study extended up to 10 years after
the hospital admission, including 93,419 patient-years and a
median of 8.6 years of follow-up.
Key ﬁndings
From a reference point of the eGFR 1 year after a hospital
admission episode, sustained subsequent 30% eGFR decline
developed in 1660 of 14,651 patients (11.3%; 14.8% for AKI,
10.8% for no AKI), and sustained new CKD stage 4 occurredKidney International (2017) 92, 440–452in 632 of 14,106 patients (4.5%; 7.1% for AKI, 4.1% for no
AKI). Overall, patients were more likely to die than experi-
ence subsequent renal progression, whether deﬁned as 30%
renal decline (37.5% vs. 11.3%) or as new CKD stage 4
(38.8% vs. 4.5%).
Characteristics of patients with and without AKI
Table 1 describes the characteristics of patients with and
without AKI during the index hospital admission. Those with
AKI (vs. no AKI)were older andweremore frequently admitted
on an emergency basis or to a critical care setting. They had
more comorbidities. Although pre-hospital episode baseline
eGFR was higher among those with AKI, post-discharge eGFR
was lower, and a greater proportion of patients had a 30%
decline in eGFR from the pre-hospital episode to the post-
hospital episode (25.7% AKI, 2.3% no AKI) (i.e., non-
recovery). Nonrecovery was especially common among patients
with AKI and post-episode eGFR < 60 ml/min per 1.73 m2
(42.3%). The proportion of patients with post-episode pro-
teinuria was also 3-fold higher among those with AKI.
Crude proportions and cumulative rates of subsequent renal
progression
Figure 3 shows the crude proportions of people alive 1 year
after hospital discharge who subsequently experienced renal
decline (top plot), de novo CKD stage 4 (bottom plot), and
death before progression during the study follow-up period
until 10 years after discharge. After AKI (vs. no AKI), there
was an excess of renal decline, or decline and death outcomes441
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Figure 2 | Flow diagram showing derivation of the cohort from the Grampian population. AKI, acute kidney injury; RRT, renal replacement
therapy.
c l i n i ca l i nves t iga t i on S Sawhney et al.: Renal progression in AKI survivorscombined, among those with post-episode eGFR $ 60 ml/
min per 1.73 m2. This excess was not present among those
with a lower post-episode eGFR. The outcome of de novo442CKD stage 4 was also more common among those with AKI,
but uncommon among those with post-episode eGFR $ 60
ml/min per 1.73 m2 (1.5% AKI, 0.7% no AKI) and eGFRKidney International (2017) 92, 440–452
Table 1 | Baseline characteristics for patients with and without acute kidney injury
Characteristic
Overall AKI No AKI
N % N % N %
N 14,651 1966 (13.4% of cohort) 12,685 (86.6% of cohort)
Age in years (median & IQR) 69 (54–78) 73 (63–81) 68 (53–78)
Female 8317 (56.8) 1011 (51.4) 7306 (57.6)
Residential care 433 (3.0) 111 (5.6) 322 (2.5)
Deprived home locationa 1215 (8.3) 169 (8.6) 1046 (8.2)
Rural home location 4014 (27.4) 551 (28.0) 3463 (27.3)
Emergency hospital admission 8689 (59.3) 1580 (80.4) 7109 (56.0)
Medical specialty admission 7203 (49.2) 1336 (68.0) 5867 (46.3)
Critical care admission 1288 (8.8) 529 (26.9) 759 (6.0)
Intensive care admission 428 (2.9) 276 (14.0) 152 (1.2)
Length of hospital stay in days (median & IQR) 3 (1–9) 14 (7–31) 2 (1–7)
Cancer 1011 (6.9) 201 (10.2) 810 (6.4)
Cardiac failure 668 (4.6) 181 (9.2) 487 (3.8)
Cerebrovascular disease 613 (4.2) 124 (6.3) 489 (3.9)
Dementia 150 (1.0) 30 (1.5) 120 (0.9)
Diabetes 917 (6.3) 255 (13.0) 662 (5.2)
Liver disease 189 (1.3) 49 (2.5) 140 (1.1)
Myocardial infarction 735 (5.0) 182 (9.3) 553 (4.4)
Neurologic disease 76 (0.5) 20 (1.0) 56 (0.4)
Peptic disease 304 (2.1) 66 (3.4) 238 (1.9)
Peripheral vascular disease 487 (3.3) 140 (7.1) 347 (2.7)
Pulmonary disease 836 (5.7) 199 (10.1) 637 (5.0)
Rheumatic disease 312 (2.1) 68 (3.5) 244 (1.9)
Baseline (pre-episode) eGFR (median & IQR) 66.8 (53.0–88.2) 75.3 (53.9–91.8) 65.8 (52.9–87.3)
Post-episode eGFRb
$60 9004 (61.5) 955 (48.6) 8049 (63.5)
45–59 3369 (23.0) 444 (22.6) 2925 (23.1)
30–44 1733 (11.8) 374 (19.0) 1359 (10.7)
<30 545 (3.7) 193 (9.8) 352 (2.8)
Intra-episode background change in eGFRc
>30% rise 1135 (7.7) 67 (3.4) 1068 (8.4)
10%–30% rise 2069 (14.1) 120 (6.1) 1949 (15.4)
No change 7654 (52.2) 517 (26.3) 7137 (56.3)
10%–30% fall 2990 (20.4) 757 (38.5) 2233 (17.6)
>30% fall 803 (5.5) 505 (25.7) 298 (2.3)
Post-episode proteinuriad
Untested 13069 (89.2) 1550 (78.8) 11519 (90.8)
Normal 753 (5.1) 136 (6.9) 617 (4.9)
Abnormal 829 (5.7) 280 (14.2) 549 (4.3)
AKI stage
0 12685 (86.6) n/a – 12685 (100.0)
1 1355 (9.2) 1355 (68.9) n/a –
2 410 (2.8) 410 (20.9) n/a –
3 201 (1.4) 201 (10.2) n/a –
Prior AKI episodes 1358 (9.3) 356 (18.1) 1002 (7.9)
AKI, acute kidney injury; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; n/a, not applicable.
aMost deprived quintile of the Scottish Index of Multiple Deprivation.
bPost-episode eGFR was the most recent available eGFR at a time point 1 year after discharge from the index hospital admission. This was used as the reference for
determining subsequent renal outcomes.
cIntra-episode background change in eGFR was the change between pre-episode baseline and post-episode eGFR (that can occur irrespective of the presence of AKI).
dPost-episode proteinuria was based on proteinuria measurements taken during or within 1 year of the index hospital admission.
S Sawhney et al.: Renal progression in AKI survivors c l i n i ca l i nves t iga t ion45–59 ml/min per 1.73 m2 (6.1% AKI, 4.8% no AKI),
compared with eGFR 30–44 ml/min per 1.73 m2 (22.5% AKI,
22.7% no AKI). Supplementary Figure S1 shows crude out-
comes at 5 years after hospital discharge, with similar re-
lationships, but with fewer deaths.
Figure 4 shows the cumulative incidences of subsequent
renal decline (a and b) and de novo CKD stage 4 (c and d)
stratiﬁed by AKI and post-episode eGFR, accounting for the
competing risk of death. Follow-up in all plots starts 1 year
after discharge (i.e., study entry). Death without progression
was more common than either progression outcome, and inKidney International (2017) 92, 440–452the absence of a post-episode eGFR < 60 ml/min per 1.73 m2,
de novo CKD stage 4 was rare.
Characteristics of patients with and without subsequent renal
progression
Table 2 describes the baseline characteristics of patients who
progressed, died, or were alive without subsequent progres-
sion at the end of the study. Those with subsequent pro-
gression by either deﬁnition were older and had more
comorbidities, including baseline renal impairment, as were
those who died. A greater proportion of patients who443
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Figure 3 | Crude long-term renal outcomes after a hospital admission episode with or without acute kidney injury (AKI). CKD, chronic
kidney disease; eGFR, estimated glomerular ﬁltration rate.
c l i n i ca l i nves t iga t i on S Sawhney et al.: Renal progression in AKI survivorsexperienced progression had diabetes as compared with those
who died without progression, whereas the reverse was true
for the other comorbidities.
Table 3 describes renal measurements within each pro-
gression group. Those with subsequent progression by either
deﬁnition had a greater proportion with a low post-episode
eGFR, proteinuria, AKI, prior AKI, and any change in
eGFR (whether a rise or fall) during the admission episode.
The proportion with post-episode proteinuria was 2-fold
higher in those with progression than in those who died
without progression. The increased progression among those
with AKI did not vary by AKI stage.
Independent association between AKI and subsequent renal
progression
Table 4 describes the multivariable-adjusted relationship be-
tween AKI and renal decline stratiﬁed by post-episode eGFR
(interaction P < 0.001). The plain text indicates relative risks444compared with a reference group with no AKI and eGFR$ 60
ml/min per 1.73 m2. Bold text indicates AKI versus no AKI at
each level of post-episode eGFR. The relative risk of renal
decline for AKI (vs. no AKI)was greater in those with otherwise
normal function than in those with lower post-episode eGFR:
hazard ratio (HR) (for AKI vs. no AKI) 2.29 (1.88–2.41), 1.50
(1.13–2.00), 0.84 (0.68–1.32) and 0.95 (0.64–1.41) for post-
episode eGFR $ 60, 45–59, 30–45, and <30 ml/min per 1.73
m2, respectively. Table 5 shows a similar relationship between
AKI and de novo CKD stage 4, but the magnitude of the vari-
ation with post-episode eGFR was greater.
Sensitivity and subgroup analyses
Supplementary Table 2 shows the interactions tested in
further analyses for the renal decline endpoint. The role of
AKI (vs. no AKI) was modiﬁed by age (interaction P value
¼ 0.01) with greater relative risk in the young than in the
elderly, but signiﬁcant in both groups. It was not modiﬁed byKidney International (2017) 92, 440–452
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Figure 4 | Cumulative incidences of subsequent renal progression (solid line) for those with (red) and without (blue) an acute kidney
injury (AKI) admission in 2003, grouped by postdischarge estimated glomerular rate (eGFR) and accounting for the competing risk of
death (dashed line). (a,b) Subsequent sustained 30% renal decline; (c,d) new chronic kidney disease (CKD) stage 4.
S Sawhney et al.: Renal progression in AKI survivors c l i n i ca l i nves t iga t iongender (P value ¼ 0.86), diabetes (P value ¼ 0.90), cancer
(P value ¼ 0.78), or cardiac failure (P value ¼ 0.23). A sta-
tistically signiﬁcant time interaction (i.e., nonproportionality)
was also present (P value ¼ 0.04), and therefore in a sensi-
tivity analysis we split follow-up at 5 years after discharge. As
reported in Supplementary Table S2, the HR for AKI up to 5
years among those alive at 1 year (1.69, 1.40–2.03) was greater
than the HR for AKI up to 10 years for those alive and at risk
5 years after discharge (1.45, 1.12–1.88). As reported inKidney International (2017) 92, 440–452Supplementary Table S3, we also repeated the analysis for AKI
versus no AKI excluding those with post-episode proteinuria,
with similar pattern results. We also repeated the analysis
excluding those who only had a discharge eGFR available for
post-episode eGFR, and the ﬁndings were unchanged. Further
sensitivity analyses included additional adjustment for acute
hospital diagnoses (Supplementary Table S4) and reanalysis
with the use of a Fine and Gray competing risks model
(Supplementary Table S5). Both showed similar results.445
Table 2 | Baseline characteristics for each progression group
Characteristic
Overall
No renal decline or
death
New sustained 30%
renal decline
Dead before 30% renal
decline
No CKD stage 4 or
death De novo CKD stage 4
Dead before de novo
CKD stage 4
N % N % N % N % N % N % N %
N 14,651 7497 (51.2% of cohort) 1660 (11.3% of cohort) 5494 (37.5% of cohort) 7996 (56.7% of cohort) 632 (4.5% of cohort) 5478 (38.8% of cohort)
Age in years (median
& IQR)
69 (54–78) 57 (42–69) 73 (65–79) 78 (71–84) 58 (43–69) 75 (69–82) 78 (70–84)
Female 8317 (56.8) 4168 (55.6) 959 (57.8) 3190 (58.1) 4485 (56.1) 353 (55.9) 3150 (57.5)
Residential care 433 (3.0) 36 (0.5) 25 (1.5) 372 (6.8) 36 (0.5) 11 (1.7) 351 (6.4)
Deprived home locationa 1215 (8.3) 624 (8.3) 126 (7.6) 465 (8.5) 646 (8.1) 50 (7.9) 476 (8.7)
Rural home location 4014 (27.4) 2137 (28.5) 447 (26.9) 1430 (26.0) 2274 (28.4) 158 (25.0) 1432 (26.1)
Emergency hospital
admission
8689 (59.3) 4027 (53.7) 939 (56.6) 3723 (67.8) 4281 (53.5) 371 (58.7) 3653 (66.7)
Medical specialty admission 7203 (49.2) 3158 (42.1) 880 (53.0) 3165 (57.6) 3399 (42.5) 346 (54.7) 3139 (57.3)
Critical care admission 1288 (8.8) 634 (8.5) 166 (10.0) 488 (8.9) 692 (8.7) 63 (10.0) 482 (8.8)
Intensive care admission 428 (2.9) 217 (2.9) 60 (3.6) 151 (2.7) 236 (3.0) 20 (3.2) 160 (2.9)
Cancer 1011 (6.9) 302 (4.0) 119 (7.2) 590 (10.7) 330 (4.1) 52 (8.2) 579 (10.6)
Cardiac failure 668 (4.6) 113 (1.5) 100 (6.0) 455 (8.3) 120 (1.5) 53 (8.4) 408 (7.4)
Cerebrovascular disease 613 (4.2) 113 (1.5) 85 (5.1) 415 (7.6) 126 (1.6) 36 (5.7) 402 (7.3)
Dementia 150 (1.0) 6 (0.1) 8 (0.5) 136 (2.5) 6 (0.1) 5 (0.8) 128 (2.3)
Diabetes 917 (6.3) 242 (3.2) 183 (11.0) 492 (9.0) 271 (3.4) 92 (14.6) 453 (8.3)
Liver disease 189 (1.3) 72 (1.0) 25 (1.5) 92 (1.7) 75 (0.9) 9 (1.4) 97 (1.8)
Myocardial infarction 735 (5.0) 226 (3.0) 96 (5.8) 413 (7.5) 241 (3.0) 60 (9.5) 379 (6.9)
Neurologic disease 76 (0.5) 21 (0.3) 9 (0.5) 46 (0.8) 21 (0.3) 5 (0.8) 47 (0.9)
Peptic disease 304 (2.1) 103 (1.4) 46 (2.8) 155 (2.8) 111 (1.4) 17 (2.7) 157 (2.9)
Peripheral vascular disease 487 (3.3) 113 (1.5) 80 (4.8) 294 (5.4) 118 (1.5) 40 (6.3) 273 (5.0)
Pulmonary disease 836 (5.7) 229 (3.1) 108 (6.5) 499 (9.1) 245 (3.1) 46 (7.3) 512 (9.3)
Rheumatic disease 312 (2.1) 91 (1.2) 37 (2.2) 184 (3.3) 106 (1.3) 14 (2.2) 177 (3.2)
Baseline (pre-episode) eGFR
(median & IQR)
66.8 (53.0–88.2) 79.6 (61.8–98.7) 57.7 (46.2–70.5) 57.3 (45.8–73.7) 78.8 (61.6–97.9) 45.8 (37.4–55.4) 59.5 (49.0–75.4)
There are 14,106 patients in de novo CKD stage 4 analysis because 545 patients had eGFR<30 at study entry.
AKI, acute kidney injury; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range.
aMost deprived quintile of the Scottish Index of Multiple Deprivation.
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Table 3 | Renal measurements for each progression group
Renal measurement
Overall
No renal decline or
death
New sustained 30%
renal decline
Dead before 30% renal
decline
No CKD stage 4 or
death De novo CKD stage 4
Dead before de novo
CKD stage 4
N % N % N % N % N % N % N %
n 14,651 7497 (51.2% of cohort) 1660 (11.3% of cohort) 5494 (37.5% of cohort) 7996 (56.7% of cohort) 632 (4.5% of cohort) 5478 (38.8% of cohort)
Post-episode eGFRa
$60 9004 (61.5) 5854 (78.1) 825 (49.7) 2325 (42.3) 6282 (78.6) 73 (11.6) 2649 (48.4)
45–59 3369 (23.0) 1257 (16.8) 450 (27.1) 1662 (30.3) 1402 (17.5) 167 (26.4) 1800 (32.9)
30–44 1733 (11.8) 344 (4.6) 263 (15.8) 1126 (20.5) 312 (3.9) 392 (62.0) 1029 (18.8)
<30 545 (3.7) 42 (0.6) 122 (7.3) 381 (6.9)
Intra-episode background
change in eGFRb
>30% rise 1135 (7.7) 420 (5.6) 226 (13.6) 489 (8.9) 498 (6.2) 45 (7.1) 572 (10.4)
10%–30% rise% 2069 (14.1) 923 (12.3) 277 (16.7) 869 (15.8) 1014 (12.7) 102 (16.1) 909 (16.6)
No change 7654 (52.2) 4659 (62.1) 703 (42.3) 2292 (41.7) 4933 (61.7) 243 (38.4) 2344 (42.8)
10%–30% fall 2990 (20.4) 1282 (17.1) 362 (21.8) 1346 (24.5) 1346 (16.8) 179 (28.3) 1302 (23.8)
>30% fall 803 (5.5) 213 (2.8) 92 (5.5) 498 (9.1) 205 (2.6) 63 (10.0) 351 (6.4)
Post-episode proteinuriac
Untested 13069 (89.2) 6985 (93.2) 1302 (78.4) 4782 (87.0) 7416 (92.7) 469 (74.2) 4809 (87.8)
Normal 753 (5.1) 340 (4.5) 122 (7.3) 291 (5.3) 386 (4.8) 51 (8.1) 291 (5.3)
Abnormal 829 (5.7) 172 (2.3) 236 (14.2) 421 (7.7) 194 (2.4) 112 (17.7) 378 (6.9)
AKI stage
0 12685 (86.6) 6912 (92.2) 1369 (82.5) 4404 (80.2) 7359 (92.0) 507 (80.2) 4467 (81.5)
1 1355 (9.2) 387 (5.2) 201 (12.1) 767 (14.0) 432 (5.4) 86 (13.6) 711 (13.0)
2 410 (2.8) 124 (1.7) 57 (3.4) 229 (4.2) 128 (1.6) 26 (4.1) 219 (4.0)
3 201 (1.4) 74 (1.0) 33 (2.0) 94 (1.7) 77 (1.0) 13 (2.1) 81 (1.5)
Prior AKI episodes 1358 (9.3) 355 (4.7) 230 (13.9) 773 (14.1) 379 (4.7) 110 (17.4) 705 (12.9)
There are 14,106 patients in de novo CKD stage 4 analysis because 545 patients had eGFR<30 at study entry.
AKI, acute kidney injury; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate.
aPost-episode eGFR was the most recent available eGFR at a time point 1 year after discharge from the index hospital admission. This was used as the reference for determining subsequent renal outcomes.
bIntra-episode background change in eGFR was the change between pre-episode baseline and post-episode eGFR (that can occur irrespective of the presence of AKI).
cPost-episode proteinuria was based on proteinuria measurements taken during or within 1 year of the index hospital admission.
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Table 4 | Relative risk of subsequent sustained 30% renal decline after acute kidney injury
Post-hospital
episode eGFR AKI or no AKI N
Cause-speciﬁc renal
decline; age-sex adjusted
(HR, 95% CI)
Cause-speciﬁc renal
decline; fully adjusted
(HR, 95% CI)
Competing event of death without
renal decline; age-sex adjusted
(HR, 95% CI)
Competing event of death without
renal decline; fully adjusted
(HR, 95% CI)
eGFR $ 60 No AKI (reference) 8049 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
AKI 955 2.01 (1.68-2.41) 2.29 (1.88-2.78) 1.77 (1.59-1.97) 1.51 (1.35-1.70)
AKI vs. no AKI 2.01 (1.68-2.41) 2.29 (1.88-2.78) 1.77 (1.59-1.97) 1.51 (1.35-1.70)
eGFR 45–59 No AKI 2925 1.14 (1.00-1.30) 1.22 (1.07-1.40) 0.98 (0.91-1.05) 0.97 (0.90-1.04)
AKI 444 1.51 (1.16-1.97) 1.84 (1.38-2.45) 1.52 (1.33-1.73) 1.21 (1.05-1.39)
AKI vs. no AKI 1.32 (1.01-1.73) 1.50 (1.13-2.00) 1.56 (1.37-1.77) 1.25 (1.09-1.44)
eGFR 30–44 No AKI 1359 1.63 (1.38-1.93) 1.71 (1.44-2.02) 1.29 (1.18-1.40) 1.18 (1.08-1.29)
AKI 374 1.38 (1.01-1.87) 1.61 (1.16-2.24) 1.64 (1.43-1.87) 1.24 (1.07-1.44)
AKI vs. no AKI 0.84 (0.61-1.16) 0.94 (0.68-1.32) 1.27 (1.11-1.46) 1.05 (0.91-1.22)
eGFR < 30 No AKI 352 3.78 (2.98-4.80) 3.81 (2.97-4.88) 1.87 (1.62-2.15) 1.65 (1.42-1.90)
AKI 193 3.36 (2.40-4.69) 3.63 (2.52-5.22) 2.20 (1.85-2.63) 1.57 (1.29-1.90)
AKI vs. no AKI 0.89 (0.69-1.30) 0.95 (0.64-1.41) 1.18 (0.96-1.45) 0.95 (0.77-1.18)
Multivariable cause-speciﬁc Cox regression with interaction terms between AKI and baseline eGFR. Adjusted estimates are reported with reference to no AKI and eGFR > 60 (plain type), and for AKI versus no AKI within each eGFR
group calculated using the interaction terms (bold type). The “fully adjusted” model included adjustment for social, demographic, admission circumstances, each separate nonrenal Charlson comorbidity, and renal measurements
as described in the Covariates section.
AKI, acute kidney injury; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate (ml/min per 1.73 m2); HR, hazard ratio.
Table 5 | Relative risk of de novo CKD stage 4 after acute kidney injury
Post-hospital
episode eGFR AKI or no AKI N
Cause-speciﬁc new CKD 4;
age-sex adjusted
(HR, 95% CI)
Cause-speciﬁc new
CKD 4; fully adjusted
(HR, 95% CI)
Competing event of death without
renal decline; age-sex adjusted
(HR, 95% CI)
Competing event of death without
renal decline; fully adjusted
(HR, 95% CI)
eGFR $ 60 No AKI (reference) 8049 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
AKI 955 2.36 (1.31-4.24) 2.55 (1.41-4.64) 1.70 (1.54-1.88) 1.47 (1.32-1.63)
AKI vs. no AKI 2.36 (1.31-4.24) 2.55 (1.41-4.64) 1.70 (1.54-1.88) 1.47 (1.32-1.63)
eGFR 45–59 No AKI 2925 7.09 (5.07-9.90) 7.18 (5.14-10.02) 0.93 (0.87-1.00) 0.94 (0.87-1.00)
AKI 444 10.96 (6.82-17.62) 12.60 (7.63-20.81) 1.46 (1.29-1.65) 1.17 (1.02-1.34)
AKI vs. no AKI 1.55 (1.02-2.34) 1.75 (1.13-2.71) 1.56 (1.38-1.77) 1.25 (1.09-1.43)
eGFR 30–44 No AKI 1359 48.54 (35.22-66.91) 50.21 (36.31-69.43) 1.18 (1.08-1.29) 1.10 (1.00-1.20)
AKI 374 52.40 (36.36-75.52) 61.17 (40.73-91.87) 1.47 (1.28-1.69) 1.12 (0.95-1.31)
AKI vs. no AKI 1.08 (0.85-1.38) 1.22 (0.92-1.61) 1.25 (1.08-1.45) 1.02 (0.87-1.19)
Multivariable cause-speciﬁc Cox regression with interaction terms between AKI and baseline eGFR. Adjusted estimates are reported with reference to no AKI and eGFR > 60 (plain type) and for AKI versus no AKI within each eGFR
group calculated using the interaction terms (bold type). The “fully adjusted” model included adjustment for social, demographic, admission circumstances, each separate nonrenal Charlson comorbidity, and renal measurements
as described in the Covariates section.
AKI, acute kidney injury; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate (ml/min per 1.73 m2); HR, hazard ratio.
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S Sawhney et al.: Renal progression in AKI survivors c l i n i ca l i nves t iga t ionDISCUSSION
This large analysis of hospital survivors after AKI isolates the
risk of long-term subsequent progression of kidney disease
from progression that has already arisen because of an initial
step drop in kidney function (incomplete recovery). When
this novel approach was used, AKI during a hospital admis-
sion was associated with increased subsequent renal progres-
sion irrespective of how progression was deﬁned, irrespective
of proteinuria or AKI severity, and even if post-episode
kidney function was normal. In one of the longest observa-
tion periods of any renal progression study, the excess risk
after AKI diminished over time but persisted throughout the
10 years of the study.
Previous studies have also shown an association between
AKI and long-term CKD,1–4 but our analysis extends the
current understanding by providing greater detail and preci-
sion. First, to the best of our knowledge, no previous studies
of AKI prognosis have presented renal progression endpoints
both deﬁned in terms of an intermediate outcome (30% renal
decline) and a hard outcome (de novo CKD stage 4 or
long-term RRT). This analysis shows that no matter how
renal progression is deﬁned, AKI is associated with poorer
long-term outcomes, although we recognize that de novo
CKD stage 4 was most common among those with AKI who
already had a low eGFR. Second, previous analyses have used
an all-or-nothing “renal recovery” dichotomy as a risk factor
for prognostic study in AKI.8,9 However, grouping patients in
this way does not separate the initial renal decline
(i.e., nonrecovery to baseline that is already observable after
the episode) from subsequent renal decline (the uncertainty of
what happens next), nor does it account for intra-episode
changes in eGFR that can occur irrespective of AKI.2 Our
analysis provides the following important detail: whereas
25.7% of people with AKI experienced a 30% decline between
their pre-episode and post-discharge eGFR values from the
post-discharge eGFR value, 14.8% of people with AKI expe-
rienced subsequent renal decline. This represented a relative
risk of up to 2.5-fold from AKI (vs. no AKI), which varied
depending on the level of post-episode eGFR.
The interaction between AKI and post-episode eGFR is a
unique ﬁnding of this analysis. The increased relative risk
from AKI (vs. no AKI) was greatest (more than 2-fold)
among those who experienced recovery to normal levels
(eGFR $ 60), even when those with post-episode proteinuria
were excluded. This ﬁnding is in contrast to the Kidney
Disease: Improving Global Outcomes AKI guidelines,
which recommend prioritization of those with de novo CKD
at a 90- day clinical reassessment.7 However, regarding the
lack of elevated relative risk from AKI among those with a
low post-episode eGFR, we note for the reader that subse-
quent decline represents only one mode of progression.
Indeed, a step 30% eGFR drop during admission was
particularly common among those with AKI and low post-
episode eGFR, indicating that nonrecovery with low subse-
quent progression was common. The interaction between
AKI and eGFR on progression also complements previousKidney International (2017) 92, 440–452studies, which have demonstrated a similar interaction be-
tween AKI and eGFR on mortality.11,12 Finally, a comple-
mentary explanation for the poorer outcomes among those
with a normal post-episode eGFR could be that AKI indicates
a “failed stress test” unmasking subclinical renal disease. This
is biologically plausible because some people with ostensibly
“normal” kidney function nevertheless lack functional
glomerular ﬁltration reserve.13 The important clinical
implication is that such patients will be more vulnerable to
future decline, even though currently available metrics of
renal function remain “normal.” In this situation a recent
AKI episode yields important prognostic information that
may otherwise be overlooked if not clearly communicated at
any transitions in care.
A strength of this analysis is the use of routinely collected
data within a large regional population with long follow-up.
This “real-life” situation maximizes the generalizability of
our ﬁndings. Another strength is the distinction of 2 per-
spectives on progression by using both intermediate (30%
renal decline) and hard (CKD stage 4) endpoints. Moreover,
by deﬁning the study entry eGFR at a post-discharge time
point, our analysis provides a precise separation of incomplete
initial recovery and subsequent renal decline that has not
previously been studied. A limitation is that data collection
was not protocolized. This means there may be ascertainment
biases in our determination of renal progression, but these
will have been partially offset by our requirement for the
outcomes to be sustained for at least 90 days. We also con-
ducted a sensitivity analysis excluding patients with only a
discharge creatinine value available in the ﬁrst post-episode
year, with unchanged results. Similarly, quantiﬁed protein-
uria was frequently not tested in the cohort. In most cases this
will have been because of a low level of suspicion for pro-
teinuria or a negative urinalysis, but some cases of proteinuria
may have been missed. We also recognize that post-AKI
proteinuria will frequently reﬂect underlying renal disease
rather than a new derangement consequent to AKI. Finally, as
with all observational studies, there will be residual con-
founding, which means that the long-term role of AKI may
have been overestimated. Our analyses included adjustment
for confounders including social, demographic, and renal
measurements; comorbid factors; and acute diagnoses in a
sensitivity analysis. However, we recognize that hospital
episode International Classiﬁcation of Diseases, 10th Revision
(ICD-10) codes for comorbidities may lack granularity. We
note that prospective recruitment and protocolized follow-up
could overcome some of these issues but would be at the
expense of “real-life” generalizability.
Overall, this study shows that no matter how severe an
AKI episode is, irrespective of proteinuria and even if post-
episode function is apparently preserved, an episode of AKI
is associated with increased subsequent renal decline that
persists for up to 10 years. Recommendations for follow-up
should therefore be formulated carefully to avoid false reas-
surance when eGFR after AKI appears to have returned to the
normal range.449
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Population
The Grampian Laboratory Outcomes Morbidity and Mortality
Study12,14,15 is a population cohort achieved by linking national and
regional data sources for a single United Kingdom health authority
(Grampian resident adult population 438,332).16 Nonresidents have
been excluded. Because data linkage avoids the need for active
recruitment, this virtual cohort is not affected by the selection biases
inherent in patient enrollment. The region includes a large tertiary
center (w1000 beds) and 2 outlying hospitals (combinedw500 beds).
All biochemistry testing was provided by a single biochemistry service
(1999–2013), regardless of clinical location (inpatient, outpatient,
community). This minimizes any loss of baseline and follow-up data,
which are vital in renal clinical research.17 Information on mortality,
hospital admission episodes, morbidity events, and long-term RRTare
available by linkage to hospital episode data, the local renal informa-
tion management system, and the Scottish Renal Registry.
Study entry
This study includes patients from the Grampian Laboratory Out-
comes Morbidity and Mortality Study who survived to the
completion of a hospital admission episode in 2003.12 We chose
1 year after discharge as the time point when the index episode was
considered complete and subjects “entered” the study. The most
recent eGFR available at study entry (1 year after an episode) was
taken as the reference value for determining all subsequent renal
outcomes. For the rest of this article, we refer to this as the “post-
episode eGFR.” Those who were dead or receiving long-term RRT at
study entry were excluded.
We selected “1 year after episode” to optimize opportunity for
renal recovery and a completeness of post-episode testing. This
testing was performed a median 264 days after discharge. As shown
in Supplementary Table S1, had study entry been earlier, post-
episode tests would have been unavailable in 39% of patients with
AKI and 55% of patients who did not have AKI. For the minority of
patients who still did not have a test at 1 year, the eGFR at discharge
was used as the reference. These patients were also removed in a
sensitivity analysis to ensure this did not affect the results.
Exposure
AKI during the index hospital admission was identiﬁed and staged
from 1 to 3 by using AKI criteria based on the Kidney Disease:
Improving Global Outcomes (KDIGO) Acute Kidney Injury Work
Group guidelines.7 Baseline creatinine values for identifying AKI
were determined by a modiﬁed “e-alert” algorithm with a hierarchy
of criteria for creatinine changes from the previous 48 hours and 7,
90, and 365 days as stated elsewhere.12 Brieﬂy, this deﬁnition for AKI
involves 1 of 3 criteria: serum creatinine level $ 1.5 times higher
than the median of all creatinine values 8 to 90 days earlier, or 91 to
365 days earlier if no tests were done between 8 and 90 days; serum
creatinine level $ 1.5 times higher than the lowest creatinine value
within 7 days; or serum creatinine level > 26 mmol/l higher than the
lowest creatinine value within 48 hours. We have previously
described this deﬁnition in more detail for studying the prognosis of
AKI in hospitals.12
Outcomes
Two subsequent renal progression outcomes are deﬁned for this
analysis: sustained 30% eGFR decline (in all 14,651 patients) and de
novo CKD stage 4 (in 14,106 patients with post-episode eGFR $ 30
ml/min per 1.73 m2). For either outcome, progression was sustained450if it lasted at least 90 days or if the patient started long-term RRT.
Notably, as illustrated in Supplementary Table S1, if a pre-episode
eGFR (instead of the post-episode eGFR) had been used as refer-
ence value for subsequent renal outcomes, 25.7% of patients with
AKI would already have had a 30% eGFR decline on the ﬁrst day of
the study (i.e., nonrecovery from AKI misclassiﬁed as post-episode
renal decline).
Follow-up
Follow-up began at study entry, 1 year after discharge from the index
hospital episode. It lasted until the date of renal progression
(respectively sustained 30% renal decline or new CKD stage 4 for
each progression subanalysis), death, or the end of study follow-up
in July 2013.
Covariates
We adjusted for all other observable renal measurements at study
entry to isolate the post-episode role of an AKI episode. These
included the most recent post-episode eGFR available at study entry,
the “intra-episode background change in eGFR,” the presence of any
other prior AKI episodes in the previous 3 years, and quantiﬁed
proteinuria during the 1-year post-episode period.
We deﬁned “intra-episode background change in eGFR” as the
difference between the pre-episode baseline eGFR and the post-
episode eGFR (Figure 1). The reason for adjusting for this change
in addition to all other renal measurements is that background rise
or fall in eGFR can occur during any admission episode, irrespective
of AKI (e.g., because of loss of muscle mass or slow background
renal progression).
All eGFR measures were reported using the Chronic Kidney
Disease Epidemiology Collaboration creatinine equation.18 We
grouped post-episode eGFR in 4 categories: $60, 45–59, 30–44,
and <30 ml/min per 1.73 m2. To allow for nonlinearity, we also
grouped intra-episode eGFR change in 5 categories: >30% rise,
10%–30% rise, no change, 10%–30% decline, and >30% decline.19
Proteinuria measures recorded as “abnormal” were albumin creati-
nine ratio $ 3 mg/mmol or protein creatinine ratio $ 15
mg/mmol.20
Nonrenal comorbidities were determined using ICD-10 codes for
Charlson comorbidities from the 5 years before admission as pre-
viously described and validated.21 Social and demographic measures
included age, sex, whether the patient was in residential care, and
home address–based measures of deprivation (most deprived quin-
tile versus the other 4 quintiles of the Scottish Index of Multiple
Deprivation), and rural location (settlement of less than 3000
people).22 Metrics of admission circumstances were whether the
index hospital admission was an emergency or elective and whether
the index admission included a stay in a medical (vs. surgical) ward
or a critical care or intensive care unit.
Statistical analyses
For both renal progression outcomes (ﬁrst for 30% eGFR decline,
then for de novo CKD stage 4), we reported patient characteristics
grouped as follows: those who were alive without renal progression
at the end of follow-up, those who experienced renal progression,
and those who died without experiencing renal progression
(a competing risk).
We plotted crude outcomes both for 30% renal decline and de
novo CKD stage 4 during follow-up by AKI and eGFR category. We
also estimated and plotted the cumulative incidence of renal pro-
gression, accounting for the competing risk of death using the StataKidney International (2017) 92, 440–452
S Sawhney et al.: Renal progression in AKI survivors c l i n i ca l i nves t iga t ioncommand “stcompet” with Stata SE 13.0 software (StataCorp LLC,
College Station, TX) as described elsewhere.23
We estimated the independent association of AKI (vs. no AKI)
with long-term renal progression in multivariable analysis using both
cause-speciﬁc Cox models for progression and death without pro-
gression. The fully adjusted model included adjustment for social,
demographic, admission circumstances, each separate nonrenal
Charlson comorbidity, and renal measurements as described previ-
ously in the Covariates section. Because an interaction exists between
eGFR (in categories $60, 45–59, 30–45, <30) and AKI (vs. no AKI)
on mortality,12,24 we included an eGFR AKI interaction term for
renal progression in this analysis. All analyses were conducted in
Stata SE 13.0 software (StataCorp LLC).
Subgroup and sensitivity analyses
We tested for interactions of AKI and progression with old age ($70
years), sex, cancer, and diabetes. We also tested an interaction with
follow-up time (per year of follow-up completed) to assess the
proportionality assumption for AKI. In the main analysis, we pre-
sented cause-speciﬁc HRs for individuals alive and at risk, which is
the preferred approach for estimating the effect of covariates on
outcomes as HRs.25 However, in sensitivity analyses, we also esti-
mated “subdistribution HRs” according to the Fine and Gray model
(in which those who died without progression remain in the “risk
set”).25,26 Because it is not possible to distinguish whether acute
diagnoses recorded during the index admission were a cause or
consequence of AKI, we did not adjust for acute diagnoses in the
primary multivariable analysis, but in a sensitivity analysis, we
compared the ﬁndings after acute hospital diagnoses (extracted from
ICD-10 codes) were added to the models.12,27 Because the most
recent available post-episode eGFR was at discharge for 20% of the
patients, we also repeated the analysis excluding these patients.
Finally, because it is possible for patients to have a normal eGFR ($
60 ml/min per 1.73 m2) but still have proteinuric evidence of non-
recovery,20 we repeated the analysis excluding those with abnormal
proteinuria measurements.
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